BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
What's the new 'Knives Out' mystery about? Everything to know about 'Wake Up Dead Man,' including who's in the cast and what the reviews say. - 2Wonderful Sea shores All over the Planet
- 3Display of Netanyahu's severed head 'incites public to murder PM', Likud says in official complaint
- 4Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- 5Vote In favor of Your Favored Language Interpretation Administration
- NASA unveils close-up pictures of the comet popping by from another star
- Figure out How to Store Your Gold Ventures: A Thorough Aide safely
- Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds
- Vote in favor of the field action that revives your psyche and soul!
- One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- Which salad do you believe is a definitive group pleaser? Vote!
- Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
- Doctors seek to understand why quitting antidepressants causes withdrawal for some
